144 related articles for article (PubMed ID: 15567693)
21. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Helou K; Horvath G
Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
[TBL] [Abstract][Full Text] [Related]
22. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
Larsen E; Blaakaer J
Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
[TBL] [Abstract][Full Text] [Related]
23. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
24. [2008 Update of Standards, Options: recommendations for management of patients with salivary gland malignant tumours (excluding lymphoma, sarcoma and melanoma), summary report].
Bensadoun RJ; Dassonville O; Rousmans S
Bull Cancer; 2008; 95(7):735-49. PubMed ID: 18755651
[TBL] [Abstract][Full Text] [Related]
25. [Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO].
Schmalfeldt B; du Bois A; Burges A; Emons G; Fink D; Gropp M; Hasenburg A; Jäger W; Kimmig R; Kiechle M; Kommoss F; Kreienberg R; Kuhn W; Lück HJ; Meier W; Münstedt K; Ortmann O; Pfisterer J; Richter B; Runnebaum I; Schröder W; Sehouli J; Tanner B; Wagner U; Weis J
Zentralbl Gynakol; 2006 Feb; 128(1):11-7. PubMed ID: 16450281
[TBL] [Abstract][Full Text] [Related]
26. [The impact of the pathologist on the treatment of epithelial ovarial cancer].
Zivanovic O; Braun M; Park TW; Kuhn W
Verh Dtsch Ges Pathol; 2005; 89():101-10. PubMed ID: 18035679
[TBL] [Abstract][Full Text] [Related]
27. Ovarian cancer.
Oates-Whitehead R
Clin Evid; 2004 Jun; (11):2493-506. PubMed ID: 15652119
[No Abstract] [Full Text] [Related]
28. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
29. [Clinical evaluation of the effect of chemotherapy in ovarian neoplasms].
Uher M; Slot E
Cesk Gynekol; 1971 Sep; 36(7):433-4. PubMed ID: 5110666
[No Abstract] [Full Text] [Related]
30. [The Piedmont-Liguria Cooperative Group on the treatment of malignant epithelial tumors of the ovary].
Mossetti C; Carnino F; Cottini M; Jacomuzzi A
Minerva Ginecol; 1984 Apr; 36(4):133-6. PubMed ID: 6462511
[No Abstract] [Full Text] [Related]
31. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience.
Ayhan A; Gultekin M; Taskiran C; Aksan G; Celik NY; Dursun P; Salman MC; Yuce K; Kucukali T
Am J Obstet Gynecol; 2006 Jan; 194(1):49-56. PubMed ID: 16389009
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal chemotherapy for ovarian cancer.
Hamilton CA; Berek JS
Curr Opin Oncol; 2006 Sep; 18(5):507-15. PubMed ID: 16894301
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacotherapy in ovarian carcinoma].
Pfisterer J; Du Bois A
MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
[TBL] [Abstract][Full Text] [Related]
34. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
35. Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up.
Hölscher G; Anthuber C; Bastert G; Burges A; Mayr D; Oberlechner E; Schubert-Fritschle G; Sinz S; Sommer H; Schmalfeldt B; Engel J;
Acta Obstet Gynecol Scand; 2009; 88(4):440-8. PubMed ID: 19191075
[TBL] [Abstract][Full Text] [Related]
36. [Surgical treatment of ovarian neoplasms].
Dlhos E
Cesk Gynekol; 1971 Sep; 36(7):397-400. PubMed ID: 5110653
[No Abstract] [Full Text] [Related]
37. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
38. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
39. [Endoperitoneal radioisotope therapy of malignant epithelial tumors of the ovary].
Tardy A; Boidi-Trotti A
Minerva Ginecol; 1984 Apr; 36(4):199-201. PubMed ID: 6462522
[No Abstract] [Full Text] [Related]
40. Ovarian cancer: a focus on management of recurrent disease.
Herzog TJ; Pothuri B
Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
